Visceral leishmaniasis in the New World & Africa

Indian Journal of Medical Research

Volumn 123, Issue 3, 2006, Pages 289-294

  Berman, Jonathan ^a,b  

^a National Institutes of Health ^*  (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cure rate; HIV co infection; Post kala azar dermal leishmaniasis; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; GAMMA INTERFERON; MEGLUMINE ANTIMONATE; NONSTEROID ANTIINFLAMMATORY AGENT; PAROMOMYCIN; SITAMAQUINE; STIBOGLUCONATE SODIUM;

AFRICA; BRAZIL; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; ETHIOPIA; FOLLOW UP; HUMAN; INCIDENCE; INDIA; KENYA; LEISHMANIA CHAGASI; LEISHMANIA DONOVANI; NEPHROTOXICITY; NONHUMAN; REVIEW; SUDAN; SYMPTOMATOLOGY; TREATMENT FAILURE; VISCERAL LEISHMANIASIS;

AFRICA; ANIMALS; BRAZIL; HIV INFECTIONS; HUMANS; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL;

EID: 33745186206     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Chagas E. Visceral leishmaniasis in Brazil. Science 1936; 84 : 397-8.
2. Barral A, Pedral-Sampaio D, Grimaldi JG, Momen H, McMahon-Pratt D, Ribeiro de Jesus A, et al. Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am J Trop Med Hyg 1991; 44 : 536-46.
3. Jeronimo SM, Duggal P, Braz RF, Cheng C, Monteiro GR, Nascimento ET, et al. An emerging peri-urban pattern of infection with Leishmania chagasi, the protozoan causing visceral leishmaniasis in northeast Brazil. Scand J Infect Dis 2004; 36 : 443-9.
4. Franke CR, Staubach C, Ziller M, Schluter H. Trends in the temporal and spatial distribution of visceral and cutaneous leishmaniasis in the state of Bahia, Brazil, from 1985 to 1999. Trans R Soc Trop Med Hyg 2002; 96 : 236-41.
5. Arias JR, Monteiro PS, Zicker F. The reemergence of visceral leishmaniasis in Brazil. Emerg Infect Dis 1996; 2 : 145-6.
6. Costa CH, Stewart JM, Gomes RB, Garcez LM, Ramos PK, Bozza M, et al. Asymptomatic human carriers of Leishmania chagasi. Am J Trop Med Hyg 2002; 66 : 334-7.
7. Carvalho SF, Lemos EM, Corey R, Dietze R. Performance of recombinant K39 antigen in the diagnosis of Brazilian visceral leishmaniasis. Am J Trop Med Hyg 2003; 68 : 321-4.
8. Badaro R, Jones TC, Lorenco R, Cerf BJ, Sampaio D, Carvalho EM, et al. A prospective study of visceral leishmaniasis in an endemic area of Brazil. J Infect Dis 1986; 154 : 639-49.
9. Badaro R, Jones TC, Carvalho EM, Sampaio D, Reed SG, Barral A, et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis 1986; 154 : 1003-11.
10. Carvalho EM, Barral A, Pedral-Sampaio D, Barral-Netto M, Badaro R, Rocha H, et al. Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J Infect Dis 1992; 165 : 535-40.
11. Evans TG, Teixeira MJ, McAuliffe IT, Vasconcelos I, Vasconcelos AW, Sousa Ade A, et al. Epidemiology of visceral leishmaniasis in northeast Brazil. J Infect Dis 1992; 166 : 1124-32.
12. Evans TG, Teixeira MJ, Sousa Ade Q, Pearson RD. Short report: extended follow-up of the natural history of persons infected with Leishmania chagasi. Am J Trop Med Hyg 1995; 53 : 360-1.
13. Jeronimo SM, Teixeira MJ, Sousa A, Thielking P, Pearson RD, Evans TG. Natural history of Leishmania (Leishmania) chagasi infection in Northeastern Brazil: long-term follow-up. Clin Infect Dis 2000; 30 : 608-9.
14. Santos MA, Marques RC, Farias CA, Vasconcelos DM, Stewart JM, Costa DL, et al. Predictors of an unsatisfactory response to pentavalent antimony in the treatment of American visceral leishmaniasis. Rev Soc Bras Med Trop 2002; 35 : 629-33.
15. Werneck GL, Batista MS, Gomes JR, Costa DL, Costa CH. Prognostic factors for death from visceral leishmaniasis in Teresina, Brazil. Infection 2003; 31 : 174-7.
16. Dietze R, Milan EP, Berman JD, Grogl M, Falqueto A, Feitosa TF, et al. Treatment of Brazilian kala-azar with a short course of amphocil (amphotericin B cholesterol dispersion). Clin Infect Dis 1993; 17 : 981-6.
17. Dietze R, Fagundes SM, Brito EF, Milan EP, Feitosa TF, Suassuna FA, et al. Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans R Soc Trop Med Hyg 1995; 89 : 309-11.
18. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 1998; 76 : 25-32.
19. Badaro R, Falcoff E, Badaro FS, Carvalho EM, Pedral-Sampaio D, Barral A, et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med 1990; 322 : 16-21.
20. Badaro R, Johnson WD Jr. The role of interferon-gamma in the treatment of visceral and diffuse cutaneous leishmaniasis. J Infect Dis 1993; 167 (Suppl 1) : S13-7.
21. Dietze R, Carvalho SF, Valli LC, Berman J, Brewer T, Milhous W, et al. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 2001; 65 : 685-9.
22. Rabello A, Orsini M, Disch J. Leishmania/HIV co-infection in Brazil: an appraisal. Ann Trop Med Parasitol 2003; 97 (Suppl 1) : 17-28.
23. de Beer P, el Harith A, Deng LL, Semiao-Santos SJ, Chantal B, van Grootheest M. A killing disease epidemic among displaced Sudanese population identified as visceral leishmaniasis. Am J Trop Med Hyg 1991; 44 : 283-9.
24. Zijlstra EE, Ali MS, el-Hassan AM, el-Toum IA, Satti M, Ghalib HW, et al. Kala-azar in displaced people from southern Sudan: epidemiological, clinical and therapeutic findings. Trans R Soc Trop Med Hyg 1991; 85 : 365-9.
25. Hashim FA, Ali MS, Satti M, el-Hassan AM, Ghalib HW, el Safi S, et al. An outbreak of acute kala-azar in a nomadic tribe in western Sudan: features of the disease in a previously non-immune population. Trans R Soc Trop Med Hyg 1994; 88 : 431-2.
26. Zijlstra EE, el-Hassan AM, Ismael A, Ghalib HW. Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg 1994; 51 : 826-36.
27. Zijlstra EE, el-Hassan AM, Ismael A. Endemic kala-azar in eastern Sudan: post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg 1995; 52 : 299-305.
28. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 2003; 3 : 87-98.
29. Musa AM, Khalil EA, Raheem MA, Zijlstra EE, Ibrahim ME, Elhassan IM, et al. The natural history of Sudanese post-kala-azar dermal leishmaniasis: clinical, immunological and prognostic features. Ann Trop Med Parasitol 2002; 96 : 765-72.
30. Seaman J, Pryce D, Sondorp HE, Moody A, Bryceson AD, Davidson RN. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis 1993; 168 : 715-20.
31. Seaman J, Mercer AJ, Sondorp HE, Herwaldt BL. Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Ann Intern Med 1996; 124 : 664-72.
32. Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, Seaman J, et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate and equivalent: HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001; 95 : 668-72.
33. Moore E, O'Flaherty D, Heuvelmans H, Seaman J, Veeken H, de Wit S, et al. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull World Health Organ 2001; 79 : 388-93.
34. Veeken H, Ritmeijer K, Seaman J, Davidson R. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med Int Health 2000; 5 : 312-7.
35. Anabwani GM, Ngira JA, Dimiti G, Bryceson AD. Comparison of two dosage schedules of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya. Lancet 1983; 1 : 210-3.
36. Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 1990; 84 : 221-5.
37. Sherwood JA, Gachihi GS, Muigai RK, Skillman DR, Mugo M, Rashid JR, et al. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis 1994; 19 : 1034-9.